Press releases
Filter by year
- Dec 23, 2020Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bl…
- Nov 24, 2020Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain D…
- Nov 19, 2020Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
- Nov 12, 2020Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
- Nov 10, 2020Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
- Nov 02, 2020Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
- Oct 27, 2020Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
- Oct 07, 2020Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
- Sep 08, 2020Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference
- Aug 13, 2020Urovant Sciences Reports Fiscal First Quarter 2020 Results
- Aug 06, 2020Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
- Jun 18, 2020Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
- Jun 18, 2020Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
- Jun 11, 2020Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results
- Jun 02, 2020Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market…
- May 27, 2020Urovant Sciences Appoints James Hindman to Board of Directors
- May 26, 2020Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
- May 14, 2020Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urologi…
- Mar 23, 2020Urovant Sciences Appoints James Robinson as President and Chief Executive Officer
- Mar 05, 2020Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
- Mar 02, 2020Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology
- Feb 25, 2020Urovant Sciences to Present at Cowen and Company’s 40th Annual Health Care Conference
- Feb 13, 2020Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results
- Feb 06, 2020Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results
- Feb 04, 2020Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Ov…
- Jan 17, 2020Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell
- Jan 08, 2020Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference